Soleno Therapeutics Inc Stock News

REDWOOD CITY, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it has entered into a loan and security agreement with Oxford Finance LLC and its affiliates (Oxford) for up to $200 million.

REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 9:00 AM Eastern Time.

REDWOOD CITY, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for DCCR (diazoxide choline) extended-release ta...

REDWOOD CITY, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will be presenting data from its DCCR clinical development program for the treatment of Prader-Willi syndrome (PWS) at the 62nd Annual European Society for...

Soleno Therapeutics' DCCR shows promising results in reducing hyperphagia in PWS patients. I believe its FDA approval is likely by December 27, 2024. DCCR could become the first approved treatment for PWS hyperphagia, addressing a significant unmet medical need. DCCR's unique mechanism targets PWS hyperphagia while preserving lean mass. This potentially extends its use beyond PWS to weight loss...

Soleno Therapeutics (SLNO, Financial) experienced a notable stock price increase of 9.11% following positive developments in its regulatory process. This performance far exceeded that of the S&P 500 index, which saw gains of less than 1%.

The company's Prader-Willi treatment inched closer to FDA approval.

On September 30, 2024, Janus Henderson Group PLC, a prominent investment firm, significantly increased its stake in Soleno Therapeutics Inc (SLNO, Financial) by acquiring an additional 804,805 shares. This transaction, executed at a price of $50.49 per share, has raised the firm's total holdings in Soleno to 4,163,678 shares.